Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (151-160 of 209) with videos related to

Pageof 21
Sort By:
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week studyLluís Puig, Matthias Augustin, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.
American Journal of Clinical Dermatology|July 3, 2019
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsValerie D Callender, Andrew F Alexis, Linda F Stein Gold, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 30, 2020
A Preliminary <sup>18</sup>F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic DermatitisBenjamin Ungar, Ana B Pavel, Philip M Robson, et al.
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.
Archives of Dermatological Research|November 13, 2018
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areataDaniela Mikhaylov, Ana Pavel, Christopher Yao, et al.
Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Pageof 21

Showing results (151-160 of 209) with videos related to

Sort By:
Pageof 21
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week studyLluís Puig, Matthias Augustin, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.
American Journal of Clinical Dermatology|July 3, 2019
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsValerie D Callender, Andrew F Alexis, Linda F Stein Gold, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 30, 2020
A Preliminary <sup>18</sup>F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic DermatitisBenjamin Ungar, Ana B Pavel, Philip M Robson, et al.
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.
Archives of Dermatological Research|November 13, 2018
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areataDaniela Mikhaylov, Ana Pavel, Christopher Yao, et al.
Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Pageof 21